Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

It’s also worth noting that ... its impact on Indian pharmaceutical companies is likely to be uneven. Generic-focused players will not be affected much and may even benefit from a more level ...

Today we hear from Jeremy Spivey about clinical trial outsourcing, and whether pharma companies should be looking ... of the trial process is in no way worth delays in product approval that ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

Squeezed by insurers and middlemen, independent pharmacists such as Mr Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, ...

To thrive in this environment, pharma ... worth of digital transformation in the space of just a few months – but while the industry has embraced digital tools and techniques, most companies ...

Ken Hall takes a closer look at GSK after the FTSE 100 pharmaceutical giant's positive first quarter earnings update. The ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

An Enquirer analysis found that doctors, nurses and other practitioners received $136 million from pharma and biotech ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that ...

Officials are expected to inform pharmaceutical companies about the target MFN prices within the next 30 days. Read Also Uttar Pradesh Govt Crackdown On Fake Drugs: ₹30.77 Crore Worth ...

It's no secret that brand-name drugs in the U.S. are much more expensive than they are abroad. In the spirit of fairness, the ...